(TheNewswire)
Thrive Focus:Personalized Medicine - Institutionalizing Diabetes Care for BetterPatient Outcomes
Spokane, WA – TheNewswire - October 25, 2023 – Thrive PrecisionHealth ("THRV") (formerly Thrive Global Biosafety and ChinaNew Energy Group Company (with subsidiary Thrive Testing and BiosafetyInc., "CNER" or "Company") (OTC:CNER) is pleased to announce it has entered into a binding letterof intent to acquire two diabetes clinics on Arizona.
"Our strategy to bring advanced technology todiabetes care has taken its first step in the pending acquisition ofTrue Diabetes Neuropathy and Wounds Solutions AZ, LLC.", statedGuy Zajonc, CEO and Chairman of Thrive Precision Health." "To us, the words Precision Health and Personalized Medicine meanbetter outcomes by tailoring our approach and offering individualizedtreatment to every patient using proven science. We will continue toacquire or start new specialized diabetes clinics in Arizona with agoal of thirty more sites".
THRV is developing a standardized clinical footprintthat can scale nationwide and internationally to offer Wound Care, IVTherapies, Neuropathy Treatment, and enhanced complementary protocols.Each clinic will have up to 20 IV stations and five wound caretreatment rooms, generating up to $5-6 million in total revenues perlocation. Our goal is a 35% EBITDA within each clinic. Approximately85% of services are reimbursed by third-party payors such as Medicare,Medicaid, and health insurance companies. Cash paid by the patientswill represent 15% of gross income from operations.
THRV will start with the two Arizona clinics, one inGilbert and the other in Show Low, AZ.
"We are excited to join the Thrive Precision teamwith the ability to build a national and potentially internationalplatform for diabetes care," says Dr. Jason Mulder, CEO of TrueDiabetes. "In Arizona alone, there are 600,000 1 diabetics andan estimated 2 million pre-diabetics, and the caseload far exceeds thecapacity to treat those affected. We want to help reverse thepre-diabetic condition before ulcers, amputation, and dialysisoccur."
The Arizona Department of Health Services, in theirPublished Diabetes Action Plan and Report 2023, states that yearlydirect and indirect costs of diabetes in Arizona exceed $6.8 billion.Arizona is expected to double its population by 2050 to 12 million andexpects half will be burdened by prediabetes and diabetes. For moredetails on the report, click the link below:
The acquisition is an asset purchase transaction andwill close once Thrive Precision Health completes its mandatorycredentialing in Arizona, estimated to be 60-90 days. During thishold period, THRV will advance funds to True Diabetes to continueexpanding their operations in both locations.
About Thrive Precision HealthInc.
Thrive Precision Health, Inc. ("Thrive") isbuilding a global diabetes care powerhouse. We are starting oracquiring established healthcare clinics specializing in diabetes careand bringing in three cutting-edge technologies to make them evenbetter. Our goal is to provide top-notch care to patients worldwidewith a seamless digital experience. Imagine if your healthcare was asunique as you are. We use AI and quantum biosensors to analyze datadown to the molecular level, tailoring treatments and recommendationsspecifically for you. This means no more one-size-fits-all solutions.Your health decisions will be based on yourpersonal data, ensuring you receive the most effective andpersonalized care possible. Leveraging this groundbreaking technologyand clinical services will include Wound Care, Neuropathy Care, PIRdiabetes care through advanced infusion methods, and conventional andcomplementary treatment to improve patient outcomes. All services willbe performed within a biosafety-secured facility using our biodefensetechnology to protect our suspectable patients and staff frombacterial and viral infections.
Follow:
Web: www.thriveprecision.health
Linkedin:
Twitter:
Facebook:
Important Notice RegardingForward-Looking Statements
This press release contains statements that constitute"forward-looking statements" within the meaning of Section27A of the Securities Act of 1933, as amended (the "SecuritiesAct"), and Section 21E of the Securities Exchange Act of 1934, asamended (the "Exchange Act"). All statements, other thanstatements of present or historical fact included in this pressrelease, regarding the Company's future financial performance, as wellas the Company's strategy, future operations, revenue guidance,projected costs, prospects, plans, and objectives of management areforward-looking statements. When used in this press release, the words"could," "should," "will,""may," "believe," "anticipate,""intend," "estimate," "expect,""project," the negative of such terms and other similarexpressions are intended to identify forward-looking statements.However, not all forward-looking statements contain such identifyingwords. These forward-looking statements are based on management'scurrent expectations and assumptions about future events. They arebased on currently available information as to the outcome and timingof future events. Except as otherwise required by applicable law, theCompany disclaims any duty to update any forward-looking statements,all of which are expressly qualified by the statements in thissection, to reflect events or circumstances after the date of thispress release. Nothing in this release is intended to be an offer ofsale or purchase of any securities nor a solicitation of any offer forthe sale or purchase of any securities.
China New Energy Group Company/Thrive Precision HealthContact:
Guy Zajonc
CEO
U.S. +1 (509) 230-1177
Copyright (c) 2023 TheNewswire - All rights reserved.